Telesis Bio, Inc. (TBIO)

Market Cap	95.50K -98.5%
Revenue (ttm)	17.03M -32.5%
Net Income	-47.93M
EPS	-28.02
Shares Out	1.80M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	851
Open	0.0510
Previous Close	0.0510
Day's Range	0.0510 - 0.0530
52-Week Range	0.0010 - 0.3000
Beta	2.30
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 7, 2026

About Telesis Bio

Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an in...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2011
• Employees: 39
• Stock Exchange: OTCMKTS
• Ticker Symbol: TBIO

Financial Performance

In 2023, Telesis Bio's revenue was $27.51 million, an increase of 0.27% compared to the previous year's $27.44 million. Losses were -$49.02 million, 1.14% more than in 2022.